Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc. (Nasdaq: CRXT) is a specialty pharmaceutical company that completed its SPAC business combination with Blue Water Acquisition Corp., sponsored by Blue Water Capital, in 2021. The company operates in the healthcare sector with a focus on andrology, built around JATENZO, its FDA-approved oral testosterone replacement therapy. As a post-merger public company, CRXT has maintained an active SEC filing record, including an 8-K submission dated March 1, 2023. To explore the full filing history, sponsor background, deal timeline, and real-time SPAC analytics for CRXT and hundreds of other transactions, sign up for complete access at SpacDesk.